Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Opdivo
Opdivo
Merck follows Bristol's suit, pulling Keytruda's SCLC nod. Is the FDA's accelerated approval reckoning finally here?
Fierce Pharma
Tue, 03/2/21 - 12:14 pm
Merck
Keytruda
FDA
small cell lung cancer
Opdivo
Bristol-Myers Squibb
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
PM Live
Wed, 02/10/21 - 12:09 am
Bristol Myers Squibb
Exelixix
Opdivo
Cabometyx
kidney cancer
ASCO GU: Bristol Myers touts first-in-class Opdivo win in muscle-invasive bladder cancer
Fierce Pharma
Tue, 02/9/21 - 01:02 pm
ASCO GU
Bristol-Myers Squibb
Opdivo
muscle-invasive urothelial carcinoma
Bristol Myers, Exelixis snag Opdivo-Cabometyx kidney cancer nod to challenge Merck, Pfizer
Fierce Pharma
Mon, 01/25/21 - 11:09 am
Bristol-Myers Squibb
Exelixis
Opdivo
Cabometyx
kidney cancer
FDA
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Fierce Pharma
Wed, 12/30/20 - 10:53 am
Merck
Bristol-Myers Squibb
AstraZeneca
Roche
Keytruda
Opdivo
Imfinzi
Tecentriq
China
PD-1 inhibitors
Bristol Myers Squibb’s Opdivo Brain Tumor Trial Fails Mid-Trial Assessment
BioSpace
Sat, 12/26/20 - 08:07 pm
Bristol-Myers Squibb
Opdivo
clinical trials
brain tumors
FDA kicks off review of second kidney cancer combo based on BMS’ Opdivo
Pharmaforum
Tue, 10/20/20 - 10:33 am
Bristol-Myers Squibb
Opdivo
kidney cancer
Bristol Myers Squibb Announces Phase III Results Exploring the Potential of Opdivo
BioSpace
Wed, 10/7/20 - 11:41 pm
Bristol-Myers Squibb
clinical trials
non-small cell lung cancer
Opdivo
Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma
Motley Fool
Sun, 10/4/20 - 10:59 pm
Bristol-Myers Squibb
FDA
Opdivo
Yervoy
mesothelioma
Bristol Myers Squibb's Opdivo cuts relapse risk in muscle-invasive bladder cancer
Fierce Pharma
Sat, 09/26/20 - 10:20 pm
Bristol-Myers Squibb
Opdivo
bladder cancer
#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap
Endpoints
Mon, 09/21/20 - 11:27 pm
Bristol-Myers Squibb
ESMO
Opdivo
esophageal cancer
Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
Seeking Alpha
Fri, 09/18/20 - 10:45 am
ESMO
Mirati Therapeutics
clinical trials
sitravantinib
Opdivo
urothelial cancer
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Yahoo/Zacks.com
Tue, 08/25/20 - 11:19 am
Exelixis
Cabometyx
FDA
kidney cancer
renal cell carcinoma
Bristol-Myers Squibb
Opdivo
Bristol Myers to buy Forbius in hunt for Opdivo-enhancing drugs
Fierce Biotech
Mon, 08/24/20 - 10:48 am
Bristol-Myers Squibb
M&A
Forbius
Opdivo
Merck's Keytruda sets up Opdivo showdown with esophageal cancer victory
Fierce Pharma
Thu, 08/20/20 - 10:48 am
Merck
Opdivo
esophageal cancer
Bristol Myers Squibb’s Opdivo Hits Mark in Two Phase III Studies
BioSpace
Wed, 08/12/20 - 12:31 am
Bristol-Myers Squibb
Opdivo
clinical trials
gastric cancer
esophageal cancer
Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%
Fierce Pharma
Sat, 08/8/20 - 10:46 pm
WCLC
lung cancer
mesothelioma
Bristol-Myers Squibb
Opdivo
Yervoy
clinical trials
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer
Pharmaceutical Business Review
Thu, 06/11/20 - 11:16 am
Clovis Oncology
clinical trials
Rubraca
ovarian cancer
Opdivo
Bristol-Myers Squibb
FDA approval tracker: several early decisions in May
EP Vantage
Wed, 06/3/20 - 10:24 am
FDA
Deciphera
Qinlock
Blueprint Medicines
Ayvakit
Eli Lilly
Retevmo
Bristol-Myers Squibb
Opdivo
Yervoy
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Thu, 05/14/20 - 10:56 pm
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »